DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Remicade (Infliximab) - Summary

 

-- advertisement --

WARNING

RISK OF INFECTIONS

TUBERCULOSIS (FREQUENTLY DISSEMINATED OR EXTRAPULMONARY AT CLINICAL PRESENTATION), INVASIVE FUNGAL INFECTIONS, AND OTHER OPPORTUNISTIC INFECTIONS, HAVE BEEN OBSERVED IN PATIENTS RECEIVING REMICADE. SOME OF THESE INFECTIONS HAVE BEEN FATAL (SEE WARNINGS).

PATIENTS SHOULD BE EVALUATED FOR LATENT TUBERCULOSIS INFECTION WITH A TUBERCULIN SKIN TEST.1 TREATMENT OF LATENT TUBERCULOSIS INFECTION SHOULD BE INITIATED PRIOR TO THERAPY WITH REMICADE.

 

REMICADE SUMMARY

REMICADE® is a chimeric IgG1(kappa) monoclonal antibody.

REMICADE, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate.

REMICADE is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.

REMICADE is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in patients with fistulizing Crohn's disease.

REMICADE NEWS HIGHLIGHTS

Media Articles Related to Remicade (Infliximab)

EULAR: Abatacept (Orencia) More Durable in RA than Infliximab (Remicade)
Source: MedPage Today Rheumatology [2008.06.16]

Remicade Phase 3 data show long-term psoriasis response
Source: The Doctors Lounge - Dermatology

more>>

Published Studies Related to Remicade (Infliximab)

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. [2008.06]

Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). [2008.05]

A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. [2008.05]

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. [2008.04]

Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. [2008.03]

more>>

Clinical Trials Related to Remicade (Infliximab)

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis [Completed]

Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From Cachexia [Completed]

Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies [Completed]

A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis [Completed]

A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Ulcerative Colitis [Completed]

more>>

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008